X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1269) 1269
Book Review (241) 241
Publication (144) 144
Book Chapter (12) 12
Conference Proceeding (3) 3
Dissertation (3) 3
Magazine Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (935) 935
cannabidiol (901) 901
humans (535) 535
animals (524) 524
male (497) 497
cannabinoids (427) 427
pharmacology & pharmacy (417) 417
cannabidiol - pharmacology (365) 365
neurosciences (323) 323
marijuana (293) 293
cannabis (288) 288
mice (244) 244
female (235) 235
rats (230) 230
psychiatry (207) 207
tetrahydrocannabinol (203) 203
cannabidiol - therapeutic use (201) 201
clinical neurology (201) 201
cannabidiol - administration & dosage (185) 185
adult (157) 157
delta-9-tetrahydrocannabinol (150) 150
dose-response relationship, drug (149) 149
analysis (147) 147
dronabinol - pharmacology (144) 144
cannabinoids - pharmacology (135) 135
delta-tetrahydrocannabinol (135) 135
endocannabinoid system (135) 135
pharmacology (133) 133
epilepsy (126) 126
drug combinations (117) 117
thc (114) 114
disease models, animal (106) 106
middle aged (105) 105
dronabinol - administration & dosage (104) 104
health aspects (100) 100
multiple sclerosis (99) 99
cannabinoid (97) 97
anxiety (95) 95
neurology (95) 95
medical marijuana (94) 94
treatment outcome (89) 89
receptors (88) 88
schizophrenia (88) 88
cannabinoids - therapeutic use (87) 87
double-blind (85) 85
inflammation (85) 85
brain (83) 83
care and treatment (83) 83
double-blind method (83) 83
rats, wistar (82) 82
research (81) 81
pain (79) 79
multiple-sclerosis (77) 77
cbd (76) 76
seizures (75) 75
time factors (75) 75
anandamide (74) 74
dronabinol - therapeutic use (72) 72
drug therapy (72) 72
young adult (70) 70
clinical trials (69) 69
spasticity (69) 69
oxidative stress (67) 67
receptor (66) 66
cannabinoid receptors (65) 65
dronabinol (65) 65
mental disorders (65) 65
multiple sclerosis - drug therapy (65) 65
cannabidiol - adverse effects (64) 64
plant extracts - therapeutic use (64) 64
administration, oral (62) 62
adolescent (62) 62
cannabinoid receptor (62) 62
usage (62) 62
behavioral sciences (60) 60
in-vitro (60) 60
article (59) 59
drug interactions (59) 59
cannabis - chemistry (58) 58
phenols (58) 58
sativex (58) 58
biochemistry & molecular biology (57) 57
drugs (57) 57
mice, inbred c57bl (57) 57
psychosis (57) 57
rodents (57) 57
biomedicine (56) 56
muscle spasticity - drug therapy (56) 56
neuroprotection (56) 56
dronabinol - analogs & derivatives (55) 55
cb1 (53) 53
endocannabinoids (53) 53
pharmacokinetics (53) 53
brain - drug effects (52) 52
in-vivo (51) 51
studies (51) 51
behavior, animal - drug effects (50) 50
digestive system diseases (50) 50
drug abuse (50) 50
activation (49) 49
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1272) 1272
Spanish (3) 3
German (2) 2
Portuguese (2) 2
Danish (1) 1
Hungarian (1) 1
Japanese (1) 1
Norwegian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 11/2017, Volume 109, pp. 21 - 30
The lipophilic phytocannabinoids cannabidiol (CBD) and Δ -tetrahydrocannabinol (THC) show therapeutic efficacy in various medical conditions. Both molecules... 
Cannabinoids | Oral bioavailability | Piperine | SNEDDS | First pass effect | RESVERATROL | CURCUMIN | P-GLYCOPROTEIN | UDP-GLUCURONOSYLTRANSFERASE | IN-VITRO | LIPID-BASED FORMULATIONS | METABOLISM | PHARMACOKINETICS | ENZYMES | PHARMACOLOGY & PHARMACY | Polyunsaturated Alkamides - chemistry | Emulsions | Stilbenes - administration & dosage | Cannabidiol - administration & dosage | Excipients - pharmacokinetics | Nanoparticles - chemistry | Rats, Wistar | Alkaloids - pharmacokinetics | Curcumin - chemistry | Biological Availability | Male | Stilbenes - chemistry | Benzodioxoles - administration & dosage | Curcumin - administration & dosage | Drug Delivery Systems | Lipids - chemistry | Excipients - chemistry | Benzodioxoles - pharmacokinetics | Piperidines - pharmacokinetics | Benzodioxoles - chemistry | Cannabidiol - pharmacokinetics | Cannabidiol - chemistry | Piperidines - administration & dosage | Piperidines - chemistry | Gastrointestinal Absorption | Administration, Oral | Curcumin - pharmacokinetics | Lipids - administration & dosage | Dronabinol - pharmacokinetics | Excipients - administration & dosage | Polyunsaturated Alkamides - administration & dosage | Animals | Lipids - pharmacokinetics | Stilbenes - pharmacokinetics | Alkaloids - administration & dosage | Nanoparticles - administration & dosage | Polyunsaturated Alkamides - pharmacokinetics | Dronabinol - administration & dosage | Dronabinol - chemistry | Alkaloids - chemistry | Index Medicus
Journal Article
Neuropharmacology, ISSN 0028-3908, 10/2012, Volume 63, Issue 5, pp. 776 - 783
Cannabidiol (CBD) demonstrated short-term neuroprotective effects in the immature brain following hypoxia–ischemia (HI). We examined whether CBD... 
Rats | Neuroprotection | Cannabidiol | Newborn | Follow-up | VITRO | ERYTHROPOIETIN | MEMORY DEFICITS | MODEL | NEUROSCIENCES | SENSORIMOTOR DEFICITS | DAMAGE | ENCEPHALOPATHY | MAGNETIC-RESONANCE-SPECTROSCOPY | IN-VIVO | POSTISCHEMIC HYPOTHERMIA | PHARMACOLOGY & PHARMACY | Neuroprotective Agents - therapeutic use | Neurons - pathology | Rats, Wistar | Cerebral Cortex - pathology | Motor Activity - drug effects | Male | Hypoxia-Ischemia, Brain - pathology | Time Factors | Cannabidiol - adverse effects | Behavior, Animal - drug effects | Female | Cannabidiol - therapeutic use | Cerebral Cortex - drug effects | Neuroprotective Agents - adverse effects | Neurons - drug effects | Psychomotor Disorders - prevention & control | Disease Models, Animal | Animals, Newborn | Hypoxia-Ischemia, Brain - drug therapy | Neurons - immunology | Random Allocation | Psychomotor Disorders - etiology | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Reperfusion Injury - prevention & control | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Cerebral Cortex - immunology | Cerebral Cortex - growth & development | Hypoxia-Ischemia, Brain - immunology | Oxidative Stress - drug effects | Brain | Brain damage | Universities and colleges | Injuries | Index Medicus | Neonates | Oxidative stress | Oxygen | Electrocoagulation | Inflammation | Neuroprotective agents | Western blotting | Magnetic resonance spectroscopy | Side effects | Magnetic resonance imaging | Excitotoxicity | Carotid artery | Brain injury
Journal Article
Journal of Neuroinflammation, ISSN 1742-2094, 01/2012, Volume 9, Issue 1, pp. 8 - 8
Background: Alzheimer's disease (AD) brain shows an ongoing inflammatory condition and non-steroidal anti-inflammatories diminish the risk of suffering the... 
Interleukin 6 | Cannabinoids | Glial activation | Anti-inflammatories | β-amyloid peptide | Tumor necrosis factor-α | Alzheimer's disease | ACTIVATION | CANNABIDIOL | ALZHEIMERS-DISEASE | MEMORY DEFICITS | beta-amyloid peptide | ENDOCANNABINOID SYSTEM | PATHOLOGY | IMMUNOLOGY | anti-inflammatories | NEUROSCIENCES | tumor necrosis factor-alpha | interleukin 6 | glial activation | IN-VIVO | PROTEIN EXPRESSION | cannabinoids | CENTRAL-NERVOUS-SYSTEM | RECEPTOR AGONIST | Encephalitis - prevention & control | Alzheimer Disease - complications | Cognition Disorders - diagnostic imaging | Encephalitis - diagnostic imaging | Humans | Choroid Plexus - metabolism | Fluorodeoxyglucose F18 - metabolism | Glycogen Synthase Kinase 3 beta | Positron-Emission Tomography | RNA, Messenger - metabolism | Corpus Striatum - metabolism | Cognition Disorders - prevention & control | Time Factors | Cyclooxygenase 2 - genetics | Cognition Disorders - etiology | Amyloid beta-Peptides - metabolism | Microglia - pathology | Disease Models, Animal | Benzoxazines - administration & dosage | Enzyme-Linked Immunosorbent Assay | Microglia - drug effects | Administration, Oral | Cannabinoids - administration & dosage | Choroid Plexus - pathology | Gene Expression Regulation - genetics | Morpholines - administration & dosage | Mice, Transgenic | Glycogen Synthase Kinase 3 - metabolism | Gene Expression Regulation - drug effects | Receptor, Cannabinoid, CB2 - metabolism | Amyloid beta-Protein Precursor - genetics | Animals | Analysis of Variance | Naphthalenes - administration & dosage | Cyclooxygenase 2 - metabolism | Corpus Striatum - drug effects | Mice | Alzheimer Disease - genetics | Encephalitis - etiology | Index Medicus | tumor necrosis factor-α
Journal Article
Psychopharmacology, ISSN 0033-3158, 5/2012, Volume 221, Issue 2, pp. 239 - 247
Several pre-clinical and human-based studies have shown that acutely administered cannabidiol (CBD) can produce anxiolytic-like effectsThe present study... 
Neurosciences | Cannabinoids | Biomedicine | CREB | BDNF | Cannabidiol | Anxiety | Pharmacology/Toxicology | Psychiatry | Hippocampus | ERK | FREEZING BEHAVIOR | CARDIOVASCULAR-RESPONSES | DEPRESSION | 5-HT1A RECEPTORS | PSYCHIATRY | CONDITIONED FEAR | NEUROSCIENCES | CANNABINOID RECEPTOR | MOOD DISORDERS | PHARMACOLOGY & PHARMACY | DIFFERENTIAL MODULATION | STRESS | BRAIN | Cannabidiol - administration & dosage | Mitogen-Activated Protein Kinase 3 - genetics | Motor Activity - drug effects | Rats | Male | Hippocampus - drug effects | Corpus Striatum - metabolism | Blotting, Western | Cerebral Cortex - metabolism | Gene Expression Regulation - drug effects | Hippocampus - metabolism | Animals | Cannabidiol - toxicity | Mitogen-Activated Protein Kinase 3 - metabolism | Mitogen-Activated Protein Kinase 1 - genetics | Corpus Striatum - drug effects | Behavior, Animal - drug effects | Anxiety - chemically induced | Cerebral Cortex - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | Proteins | Brain | Antianxiety agents | Protein binding | Gene expression | Animal behavior | Rodents | Chronic illnesses | Index Medicus | Drugs | Transcription factors | Extracellular signal-regulated kinase | Immunoblotting | Cyclic AMP response element-binding protein | Anxiolytics | Emotions | Brain-derived neurotrophic factor | Antidepressants | Cortex (frontal) | Neostriatum | Protein-tyrosine kinase receptors | TrkB receptors | Tonic immobility | Locomotor activity
Journal Article
Experimental and Clinical Psychopharmacology, ISSN 1064-1297, 08/2017, Volume 25, Issue 4, pp. 242 - 248
Despite widespread cannabis use in humans, few rodent models exist demonstrating significant Δ⁹-tetrahydrocannabinol (THC) self-administration, possibly due to... 
Self-administration | Sex differences | Drug interaction | CBD | THC | Cannabidiol - administration & dosage | Rats, Long-Evans | Rats | Cannabidiol - pharmacology | Male | Dose-Response Relationship, Drug | Cocaine - administration & dosage | Administration, Intravenous | Self Administration | Animals | Sex Factors | Female | Dronabinol - administration & dosage | Index Medicus
Journal Article
Biological Psychiatry, ISSN 0006-3223, 10/2018, Volume 84, Issue 8, pp. 601 - 610
Cannabis is the most widely used illicit drug, but knowledge of the neurological consequences of cannabis use is deficient. Two primary components of cannabis... 
Nucleus accumbens | Δ9-tetrahydrocannabinol | Drug abuse | Cannabidiol | Reinstatement | Synaptic plasticity | tetrahydrocannabinol | Δ
Journal Article
Pharmacological Reports, ISSN 1734-1140, 12/2017, Volume 69, Issue 6, pp. 1247 - 1253
Journal Article
14.